EXTERNAL FUNDING Federal Pharmaceutical / THE PERMANENTE MEDICAL GROUP / Case / DOR / /
Currency
USD / /
Event
Employment Change / Environmental Issue / /
Facility
University of California Berkeley / Columbia University / Northern California Institute / National Institute of Environmental Health Sciences Total Project Period / University of California / /
IndustryTerm
health services / alcoholic beverage choice / member services / /
MedicalCondition
respiratory and cardiovascular disease / HIV / Colorectal Cancer / Prostate Cancer / illness / Breast Cancer / asthma / prior illness / HIV Infection / future asthma / insulin resistance / lipodystrophy / CANCER / disease / Cervical Cancer / CARDIOVASCULAR DISEASE / DIABETES / NEUROLOGICAL DISEASE / renal insufficiency / preatherogenic hyperlipidemia / AIDS / severe asthma / syndrome / /
Kaiser Permanente's Institutional Review Board / Northern / Columbia University / University of California / National Institute of Environmental Health Sciences Total Project Period / National Institute of Health / CDC / Department of Medical Methods Research / Garfield Memorial Fund / Division of Research / Northern California Institute for Research Education Total Project Period / University of California / Davis / Kaiser Permanente / AHRQ / Environmental Protection Agency / /
Person
Rachel Whitmer / Joe V. Selby / Henry J. Kaiser / Stephen Sidney / Arthur L. Klatsky / Carlos Iribarren / Sidney R. Garfield / Gerald N. DeLorenze / Morris F. Collen / Lawrence Kushi / Stephen K. Van Den Eeden / /
Position
Principal Investigator / MPH Director / Physician / General / DIRECTOR EMERITUS / Director for Etiology and Prevention Research / present DIRECTOR / DIRECTOR / /
TABLE OF CONTENTS VISION STATEMENT ...................................................................................................... 3 A MESSAGE FROM DOR’S DIRECTOR EMERITUS ......................................